Savella

Savella is a brand name of milnacipran, approved by the FDA in the following formulation(s):

SAVELLA (milnacipran hydrochloride - tablet; oral)

• 
  Manufacturer: CYPRESS BIOSCIENCE
  
  Approval date: January 14, 2009
  
  Strength(s): 100MG, 12.5MG, 25MG, 50MG ^[RLD]

Has a generic version of Savella been approved?

No. There is currently no therapeutically equivalent version of Savella available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Savella. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods of treating fibromyalgia
  Patent 6,602,911
  Issued: August 5, 2003
  Inventor(s): Jay D.; Kranzler & Srinivas G.; Rao
  Assignee(s): Cypress Bioscience, Inc.
  The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
  
  Patent expiration dates:
  
  
  • November 5, 2021
    
    ✓ 
    Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
  
  



• 
  Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
  Patent 6,992,110
  Issued: January 31, 2006
  Inventor(s): Kranzler; Jay D. & Rao; Srinivas G.
  Assignee(s): Cypress Bioscience, Inc.
  The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
  
  Patent expiration dates:
  
  
  • November 5, 2021
    
    ✓ 
    Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
  
  



• 
  Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
  Patent 7,888,342
  Issued: February 15, 2011
  Inventor(s): Kranzler; Jay D. & Rao; Srinivas G.
  Assignee(s): Cypress Bioscience, Inc.
  The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
  
  Patent expiration dates:
  
  
  • November 5, 2021
    
    ✓ 
    Patent use: MANAGEMENT OF FIBROMYALGIA (FM)
  
  



• 
  Milnacipran for the long-term treatment of fibromyalgia syndrome
  Patent 7,994,220
  Issued: August 9, 2011
  Inventor(s): Rao; Srinivas G. & Gendreau; Michael & Kranzler; Jay D.
  Assignee(s): Cypress Bioscience, Inc.
  The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.
  
  Patent expiration dates:
  
  
  • September 19, 2029
    
    ✓ 
    Patent use: MANAGEMENT OF FIBROMYALGIA
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 14, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Savella Consumer Information (Drugs.com)
• Savella Consumer Information (Wolters Kluwer)
• Savella Consumer Information (Cerner Multum)
• Savella Advanced Consumer Information (Micromedex)
• Milnacipran Consumer Information (Wolters Kluwer)
• Milnacipran Consumer Information (Cerner Multum)
• Milnacipran Advanced Consumer Information (Micromedex)